Craft
Celgene

Celgene

Revenue

$15.3 B

FY, 2018

Celgene Summary

Company summary

Overview
Celgene is an integrated global biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation.
Type
Subsidiary
Founded
1986
HQ
Summit, NJ, US | view all locations
Website
http://www.celgene.com/
Cybersecurity rating
Sectors

Key people

  • Mark J. Alles

    Mark J. Alles, Chairman and Chief Executive Officer

    • Zeba M. Khan

      Zeba M. Khan, Vice President Corporate Responsibility

    • John Vogler

      John Vogler, Director Environment, Health & Safety

    • Reimund Tauer

      Reimund Tauer, Director, CAR T Commercial Operations

    Operating MetricsView all

    Phase III Trials Products (Inflammation and Immunology)

    4
    100.0%

    FY, 2018

    Filed Trials Products (Solid Tumors)

    4

    FY, 2018

    Phase I Trials Products (Cellular Therapies)

    2

    FY, 2016

    LocationsView all

    3 locations detected

    • Summit, NJ HQ

      United States

      86 Morris Ave

    • Singapore

      Singapore

      200 Newton Road #04-01, Newton 200

    • Boudry, Neuchâtel

      Switzerland

      Route de Perreux 1

    Celgene Financials

    Summary financials

    Revenue (Q3, 2019)
    $4.5B
    Gross profit (Q3, 2019)
    $4.4B
    Net income (Q3, 2019)
    $1.7B
    Cash (Q3, 2019)
    $9.6B
    EBIT (Q3, 2019)
    $2.3B

    Footer menu